Madrigal Pharmaceuticals Inc

madrigalpharma.com

Madrigal Pharmaceuticals (NASDAQ: MDGL) is a biopharmaceutical company focused on developing and commercializing therapies for liver diseases. The filing excerpts provided do not contain sufficient detail to describe Madrigal's revenue model, product portfolio, competitive position, financial metrics, geographic footprint, leadership, or founding history with the specificity required by these writing rules.

Peers: Vericel Corp Arcutis Biotherapeutics Inc Avid Bioservices, Inc. Avidity Biosciences, Inc. Emergent BioSolutions Inc Enanta Pharmaceuticals Inc Gossamer Bio Inc ImmunoGen, Inc. Sana Biotechnology Inc

Source: SEC 10-K, filed 2026-02-19

Dive deeper

Financial Snapshot

Revenue

TTM

$1.132B

Gross Margin

TTM

93.3%

Net Income

TTM

-$309.4M

Current Assets

2026 Q1

$1.182B

Current Liabilities

2026 Q1

$338.3M

Current Ratio

2026 Q1

349.53%

Total Assets

2026 Q1

$1.227B

Total Liabilities

2026 Q1

$683.9M

Book Value

2026 Q1

$543.5M

Cash

2026 Q1

$227.0M

P/E

Last 4 Quarters

N/A

Free Cash Flow

TTM

-$275.4M

Stock Price

Market Cap: $12.374 Billion